ClinicalTrials.gg
CompletedNCT01914393Updated Dec 19, 2019Results posted

Pediatric Open-Label Extension Study

A Phase 3 interventional study of Lurasidone 20, 40, 60, 80 mg, flexibly dosed in Schizophrenia, Autism and Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 88 sites in 15 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-12-19.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
702
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
Largest of 39
702 · median 149
Started
2013
with 4 others
Phase 3
18 of 39
none open now
Registered
27th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one has the largest enrollment, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 27th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326

03

Conditions studied

  • Schizophrenia
  • Autism
  • Bipolar Depression

Keywords

  • Schizophrenia
  • Autism
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' participation in the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) or Independent Ethics Committee (IEC) requirements, the subject will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.
  • Subject has completed Study D1050301 (Visit 9) OR
  • Subject has completed Study D1050325 (Visit 9) OR
  • Subject has completed Study D1050326 (Visit 8)
  • Subject is judged by the investigator to be appropriate for participation in a 104-week clinical trial in an outpatient setting involving open-label lurasidone treatment, and is able to comply with the protocol.
  • A reliable informant (eg, parent, legal guardian, or caregiver) must be available to accompany the subject at each visit. For subjects entering from Study D1050325, the reliable caregiver must also oversee the administration of the study drug throughout the study
  • Females who participate in this study:

    • are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-
    • practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-
    • are sexually active and willing to use a medically effective method of (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
  • Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.

Exclusion criteria

Exclusion Criteria:

  • Subject is considered by the investigator to be at imminent risk of suicide.
  • Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
702 participants (actual)

Study arms

  • Experimental
    Lurasidone 20, 40, 60, 80 mg, flexibly dosed

    Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily

    Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)

    The Safety population consists of all subjects who received at least one dose of study drug in this study.

    Time frame: During 104 Weeks (2-years) treatment period

Secondary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

    Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score for subjects continued from study D1050301. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210 Higher values of PANSS total score represents greater severity of illness.

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  2. Change From Baseline in PANSS Positive Subscale Score

    Change from Baseline in PANSS Positive Subscale Score for subjects continued from study D1050301 The Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness /persecution, and hostility; Positive subscale (range 7-49) is calculated as sum of Items P1 to P7 in the positive subscale Higher values of PANSS sub-scale scores represent greater severity

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  3. Change From Baseline in PANSS Negative Subscale Score

    Change from Baseline in PANSS Negative Subscale Score for subjects continued from study D1050301 The Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; Negative subscale (range 7-49) is calculated as sum of Items N1 to N7 in the negative subscale Higher values of PANSS sub-scale scores represent greater severity of illness.

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  4. Change From Baseline in PANSS General Psychopathology Subscale Score

    Change from Baseline in PANSS General Psychopathology Subscale Score for subjects continued from study D1050301 The General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation; General psychopathology subscale (range 16-112) is calculated as sum of Items G1 to G16 in the general psychopathology subscale Higher values of PANSS sub-scale scores represent greater severity of illness.

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  5. Change From Baseline in PANSS Excitability Subscale Score

    Change from Baseline in PANSS Excitability Subscale Score for subjects continued from study D1050301 Subscale of Excitability consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control. The sum of the four items ranges from 4 to 28 Higher values of PANSS sub-scale scores represent greater severity of illness.

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  6. Change From Baseline in the Clinical Global Impression -Severity Score

    Change from Baseline in the Clinical Global Impression -Severity Score for subjects continued from study D1050301 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  7. Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score

    Change from Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score for subjects continued from study D1050301 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  8. Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score

    Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050301 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  9. Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score

    Change from Baseline in ABC Irritability Subscale Score for subjects continued from study D1050325 The Aberrant Behavior Checklist (ABC) contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Irritability Subscale Score is calculated as summing of items 2, 4, 8, 10, 14, 19, 25, 29, 34, 36, 41, 47, 50, 52, and 57; as a result, ABC irritability subscale score ranges from 0 to 45. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  10. Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score

    Change from Baseline in ABC Lethargy and Social Withdrawal Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Lethargy and Social Withdrawal Subscale Score is calculated as summing of items 3, 5, 12, 16, 20, 23, 26, 30, 32, 37, 40, 42, 43, 53, 55, and 58. ABC Lethargy and Social Withdrawal Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  11. Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score

    Change from Baseline in ABC Stereotypic Behavior Subscale Score for subjects continued from study D1050325. The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Stereotypic behavior Subscale Score is calculated as summing of 6, 11, 17, 27, 35, 45, and 49 items . ABC Stereotypic behavior Subscale Score ranges from 0 to 21. Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). To score the ABC, the individual items for each subscale are simply summed to their respective totals. It is inappropriate to compute a "total aberrant score", based on a summation of all 58 items, as the subscales are largely independent. In general, higher values of ABC subscale scores represent greater severity

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  12. Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score

    Change from Baseline in ABC Hyperactivity and Noncompliance Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Hyperactivity and noncompliance Subscale Score is calculated as summing of 1, 7, 13, 15, 18, 21, 24, 28, 31, 38, 39, 44, 48, 51, 54, and 56 items. ABC hyperactivity and noncompliance Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  13. Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score

    Change from Baseline in ABC Inappropriate Speech Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Inappropriate speech Subscale Score is calculated as summing of 9, 22, 33, and 46 items. ABC inappropriate speech Subscale Score ranges from 0 to 12. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  14. Change From Baseline in Clinical Global Impression (CGI) - Severity Score

    Change from Baseline in Clinical Global Impression (CGI) - Severity Score for subjects continued from study D1050325 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  15. Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)

    Change from Baseline in CY-BOCS for subjects continued from study D1050325 CY-BOCS used in the study is a modification of the Yale-Brown Obsessive Compulsive Scale and contains total 7 items for compulsion. "Obsessions" section was removed as it is difficult to obtain valid information given typical language/cognitive delays in the population. Each item of the compulsive scale ranges from 0 to 4. At this time, item 1b ("compulsion-free interval") and item 6 ("peculiarity of the behavior") are not being used in the scoring. Item 7 is a rating for reliability, ranging from 0 (excellent) to 3 (poor). It reflects the interview's judgment regarding the confidence in the data collected hence it is not counted in the CY-BOCS total score. The CY-BOCS compulsion total score is the sums of item 1-5. As a result, the CY-BOCS compulsion total score may range from 0 to 20. In general, higher values of CY-BOCS scores represent greater severity of illness

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  16. Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score

    Change from Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score for subjects continued from study D1050325 The CGSQ is comprised of total 21 items. Each item is rated on a 5-point Likert-type scale (1 (not at all a problem) to 5 (very much a problem)) and is grouped into three subscales: objective strain, subjective externalized strain, and subjective internalized strain. The 3 subscale scores are calculated as the averages of the corresponding individual items, which range in severity from 1 to 5. Higher scores on each of these subscale scales indicate greater strain. A global strain score is calculated by summing the three subscales (i.e., objective strain, subjective externalized strain, and subjective internalized strain) to provide an indication of the total impact of the special demands on the family. Global strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  17. Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score

    Change from Baseline in CDRS-R Total Score for subjects continued from study D1050326 CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. The CDRS-R is administered separately to the patient and to the caregiver; among 17 items, 14 items are based on separate interviews with child and parent, 3 items are based solely on the rater's observation of child (ie, no questions).The 14 items are rated on a 1 (no psychopathology) to 7 (most psychopathology) scale, where a rating of 3 represents mild psychopathology. The 3 items (sleep disturbance, appetite disturbance, listless speech) are rated on a 1 (no pathology) to 5 (most pathology) scale. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  18. Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score

    Change from Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score for subjects continued from study D1050326 The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  19. Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score

    Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score for subjects continued from study D1050326 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  20. Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score

    Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050326 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  21. Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score

    Change from Baseline in PAR Total Score for subjects continued from study D1050326 The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6 17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. Scores of 8 or 9 are not counted in the summation as per the PARS instructions. The PARS total score over all 7 questions ranges in value from 0 to 35.A higher PARS total score

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

  22. Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score

    Change from Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score for subjects continued from study D1050326 The ADHD-RS IV is a validated scale that measures the behaviors of children with ADHD. The ADHD-RS IV consists of 18 items reflecting current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored from a range of 0 (no symptoms) to 3 (severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into two sub-scales: hyperactivity/impulsivity (even number items 2 through 18) and inattentiveness (odd number items 1 through 17), ranging from 0 to 27. A higher ADHD-RS total score and sub-scales scores are associated with greater illness severity

    Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104

07

Results

Posted Dec 19, 2019

Participant flow

participation in the preceding double-blind efficacy and safety studies (D1050301, NCT01911429,; D1050325, NCT01911442; or D1050326, NCT02046369) were eligible for enrollment in this study.

Participant flow — Overall Study
MilestoneRollover From D1050301Rollover From D1050325Rollover From D1050326
Started271125306
Completed15654168
Not completed11571138
Withdrew: Protocol violation11319
Withdrew: Lack of efficacy11165
Withdrew: No reason given14816
Withdrew: Adverse event291831
Withdrew: Withdrawal by subject382047
Withdrew: Lost to follow-up12619
Withdrew: Subject never dosed001

Outcome measures

PrimaryNumber of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)

The Safety population consists of all subjects who received at least one dose of study drug in this study.

Time frame:
During 104 Weeks (2-years) treatment period
Reported as:
Number · Participants
Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)
ParticipantsRollover From D1050301Rollover From D1050325Rollover From D1050326Lurasidone (All Indications)
Subjects with at least one treatment emergent AE214106252572
Subjects with at least one treatment emergent SAE28133778
Subjects with AE Leading to Discontinuation28183177
SecondaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score for subjects continued from study D1050301. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210 Higher values of PANSS total score represents greater severity of illness.

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleRollover From D1050301
Open Label Baseline76.0 ± 17.72
Week 28-11.9 ± 13.74
Week 52-15.6 ± 14.97
Week 104-18.4 ± 16.73
SecondaryChange From Baseline in PANSS Positive Subscale Score

Change from Baseline in PANSS Positive Subscale Score for subjects continued from study D1050301 The Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness /persecution, and hostility; Positive subscale (range 7-49) is calculated as sum of Items P1 to P7 in the positive subscale Higher values of PANSS sub-scale scores represent greater severity

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Positive Subscale Score
units on a scaleRollover From D1050301
Open Label baseline17.9 ± 5.51
Week 28-3.9 ± 4.68
Week 52-5.1 ± 5.13
Week 104-5.4 ± 5.66
SecondaryChange From Baseline in PANSS Negative Subscale Score

Change from Baseline in PANSS Negative Subscale Score for subjects continued from study D1050301 The Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; Negative subscale (range 7-49) is calculated as sum of Items N1 to N7 in the negative subscale Higher values of PANSS sub-scale scores represent greater severity of illness.

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Negative Subscale Score
units on a scaleRollover From D1050301
Open Label baseline20.5 ± 4.91
Week 28-2.6 ± 4.16
Week 52-3.4 ± 4.34
Week 104-4.3 ± 4.77
SecondaryChange From Baseline in PANSS General Psychopathology Subscale Score

Change from Baseline in PANSS General Psychopathology Subscale Score for subjects continued from study D1050301 The General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation; General psychopathology subscale (range 16-112) is calculated as sum of Items G1 to G16 in the general psychopathology subscale Higher values of PANSS sub-scale scores represent greater severity of illness.

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in PANSS General Psychopathology Subscale Score
units on a scaleRollover From D1050301
Open label baseline37.5 ± 9.38
Week 28-5.4 ± 7.28
Week 52-7.2 ± 7.65
Week 104-8.7 ± 8.68
SecondaryChange From Baseline in PANSS Excitability Subscale Score

Change from Baseline in PANSS Excitability Subscale Score for subjects continued from study D1050301 Subscale of Excitability consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control. The sum of the four items ranges from 4 to 28 Higher values of PANSS sub-scale scores represent greater severity of illness.

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in PANSS Excitability Subscale Score
units on a scaleRollover From D1050301
Open label baseline9.0 ± 3.73
Week 28-1.3 ± 3.09
Week 52-1.7 ± 3.31
week 104-2.1 ± 3.63
SecondaryChange From Baseline in the Clinical Global Impression -Severity Score

Change from Baseline in the Clinical Global Impression -Severity Score for subjects continued from study D1050301 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in the Clinical Global Impression -Severity Score
units on a scaleRollover From D1050301
Open label baseline4.0 ± 0.97
Week 28-0.87 ± 0.941
Week 52-1.10 ± 1.084
Week 104-1.31 ± 1.196
SecondaryChange From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score

Change from Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score for subjects continued from study D1050301 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score
units on a scaleRollover From D1050301
Open label baseline55.0 ± 11.96
Week 2810.94 ± 11.943
Week 5214.28 ± 12.814
Week 10417.85 ± 15.155
SecondaryChange From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score

Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050301 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · percent of score
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score
percent of scoreRollover From D1050301
Open label baseline57.14 ± 14.850
Week 287.48 ± 13.336
Week 529.98 ± 13.541
Week 10411.74 ± 15.783
SecondaryChange From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score

Change from Baseline in ABC Irritability Subscale Score for subjects continued from study D1050325 The Aberrant Behavior Checklist (ABC) contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Irritability Subscale Score is calculated as summing of items 2, 4, 8, 10, 14, 19, 25, 29, 34, 36, 41, 47, 50, 52, and 57; as a result, ABC irritability subscale score ranges from 0 to 45. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score
units on a scaleRollover From D1050325
Open label baseline19.0 ± 10.63
Week 28-2.1 ± 9.16
Week 52-2.9 ± 9.85
Week 104-4.2 ± 11.62
SecondaryChange From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score

Change from Baseline in ABC Lethargy and Social Withdrawal Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Lethargy and Social Withdrawal Subscale Score is calculated as summing of items 3, 5, 12, 16, 20, 23, 26, 30, 32, 37, 40, 42, 43, 53, 55, and 58. ABC Lethargy and Social Withdrawal Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Median · score
Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score
scoreRollover From D1050325
Open label baseline10.3 ± 9.48
Week 28-0.7 ± 7.01
Week 52-1.1 ± 6.94
Week 104-1.1 ± 6.57
SecondaryChange From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score

Change from Baseline in ABC Stereotypic Behavior Subscale Score for subjects continued from study D1050325. The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Stereotypic behavior Subscale Score is calculated as summing of 6, 11, 17, 27, 35, 45, and 49 items . ABC Stereotypic behavior Subscale Score ranges from 0 to 21. Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). To score the ABC, the individual items for each subscale are simply summed to their respective totals. It is inappropriate to compute a "total aberrant score", based on a summation of all 58 items, as the subscales are largely independent. In general, higher values of ABC subscale scores represent greater severity

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · score
Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score
scoreRollover From D1050325
Open label baseline6.1 ± 5.87
Week 28-0.9 ± 3.55
Week 52-0.9 ± 4.53
Week 104-1.1 ± 4.41
SecondaryChange From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score

Change from Baseline in ABC Hyperactivity and Noncompliance Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Hyperactivity and noncompliance Subscale Score is calculated as summing of 1, 7, 13, 15, 18, 21, 24, 28, 31, 38, 39, 44, 48, 51, 54, and 56 items. ABC hyperactivity and noncompliance Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · score
Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score
scoreRollover From D1050325
Open label baseline24.1 ± 12.19
Week 28-3.8 ± 10.16
Week 52-4.3 ± 11.24
Week 104-5.6 ± 12.84
SecondaryChange From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score

Change from Baseline in ABC Inappropriate Speech Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Inappropriate speech Subscale Score is calculated as summing of 9, 22, 33, and 46 items. ABC inappropriate speech Subscale Score ranges from 0 to 12. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · score
Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score
scoreRollover From D1050325
Open label baseline5.2 ± 3.61
Week 28-0.7 ± 2.75
Week 52-0.7 ± 2.88
Week 104-0.5 ± 3.00
SecondaryChange From Baseline in Clinical Global Impression (CGI) - Severity Score

Change from Baseline in Clinical Global Impression (CGI) - Severity Score for subjects continued from study D1050325 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression (CGI) - Severity Score
units on a scaleRollover From D1050325
Open label baseline3.9 ± 1.25
Week 28-0.43 ± 0.984
Week 52-0.71 ± 1.078
Week 104-0.78 ± 1.313
SecondaryChange From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)

Change from Baseline in CY-BOCS for subjects continued from study D1050325 CY-BOCS used in the study is a modification of the Yale-Brown Obsessive Compulsive Scale and contains total 7 items for compulsion. "Obsessions" section was removed as it is difficult to obtain valid information given typical language/cognitive delays in the population. Each item of the compulsive scale ranges from 0 to 4. At this time, item 1b ("compulsion-free interval") and item 6 ("peculiarity of the behavior") are not being used in the scoring. Item 7 is a rating for reliability, ranging from 0 (excellent) to 3 (poor). It reflects the interview's judgment regarding the confidence in the data collected hence it is not counted in the CY-BOCS total score. The CY-BOCS compulsion total score is the sums of item 1-5. As a result, the CY-BOCS compulsion total score may range from 0 to 20. In general, higher values of CY-BOCS scores represent greater severity of illness

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)
units on a scaleRollover From D1050325
Open label baseline10.2 ± 5.43
Week 28-2.2 ± 3.39
Week 52-2.3 ± 4.32
Week 104-3.2 ± 4.58
SecondaryChange From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score

Change from Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score for subjects continued from study D1050325 The CGSQ is comprised of total 21 items. Each item is rated on a 5-point Likert-type scale (1 (not at all a problem) to 5 (very much a problem)) and is grouped into three subscales: objective strain, subjective externalized strain, and subjective internalized strain. The 3 subscale scores are calculated as the averages of the corresponding individual items, which range in severity from 1 to 5. Higher scores on each of these subscale scales indicate greater strain. A global strain score is calculated by summing the three subscales (i.e., objective strain, subjective externalized strain, and subjective internalized strain) to provide an indication of the total impact of the special demands on the family. Global strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · score
Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score
scoreRollover From D1050325
Open label baseline7.95 ± 2.213
Week 28-0.48 ± 1.887
Week 52-0.60 ± 2.032
Week 104-0.63 ± 2.123
SecondaryChange From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score

Change from Baseline in CDRS-R Total Score for subjects continued from study D1050326 CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. The CDRS-R is administered separately to the patient and to the caregiver; among 17 items, 14 items are based on separate interviews with child and parent, 3 items are based solely on the rater's observation of child (ie, no questions).The 14 items are rated on a 1 (no psychopathology) to 7 (most psychopathology) scale, where a rating of 3 represents mild psychopathology. The 3 items (sleep disturbance, appetite disturbance, listless speech) are rated on a 1 (no pathology) to 5 (most pathology) scale. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score
units on a scaleRollover From D1050326
Open label baseline39.2 ± 13.38
Week 28-9.9 ± 13.48
Week 52-13.4 ± 13.01
Week 104-16.4 ± 13.24
SecondaryChange From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score

Change from Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score for subjects continued from study D1050326 The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score
units on a scaleRollover From D1050326
Open label baseline3.2 ± 1.09
Week 28-1.10 ± 1.140
Week 52-1.36 ± 1.184
Week 104-1.61 ± 1.153
SecondaryChange From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score

Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score for subjects continued from study D1050326 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score
units on a scaleRollover From D1050326
Open label baseline61.1 ± 12.54
Week 2811.17 ± 13.893
Week 5214.67 ± 14.347
Week 10418.96 ± 14.898
SecondaryChange From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score

Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050326 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · score
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score
scoreRollover From D1050326
Open label baseline59.52 ± 15.569
Week 288.16 ± 16.345
Week 5211.37 ± 16.343
Week 10414.75 ± 16.744
SecondaryChange From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score

Change from Baseline in PAR Total Score for subjects continued from study D1050326 The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6 17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. Scores of 8 or 9 are not counted in the summation as per the PARS instructions. The PARS total score over all 7 questions ranges in value from 0 to 35.A higher PARS total score

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score
units on a scaleRollover From D1050326
Open label baseline8.0 ± 6.94
Week 28-2.7 ± 5.41
Week 52-3.2 ± 5.97
Week 104-4.9 ± 6.41
SecondaryChange From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score

Change from Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score for subjects continued from study D1050326 The ADHD-RS IV is a validated scale that measures the behaviors of children with ADHD. The ADHD-RS IV consists of 18 items reflecting current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored from a range of 0 (no symptoms) to 3 (severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into two sub-scales: hyperactivity/impulsivity (even number items 2 through 18) and inattentiveness (odd number items 1 through 17), ranging from 0 to 27. A higher ADHD-RS total score and sub-scales scores are associated with greater illness severity

Time frame:
Open-Label Baseline, Week 28, Week 52, and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score
units on a scaleRollover From D1050326
Open label baseline9.4 ± 10.58
Week 28-2.2 ± 6.29
Week 52-2.4 ± 5.83
Week 104-3.3 ± 6.24

Adverse events

Collected over An AE onset on or after the start of the open-label treatment period (treatment duration: 104 weeks) through 7 days after study drug discontinuation (14 days for serious adverse events and deaths). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rollover From D10503010/271 (0%)28/271 (10.3%)184/271 (67.9%)
Rollover From D10503250/125 (0%)13/125 (10.4%)94/125 (75.2%)
Rollover From D10503260/305 (0%)37/305 (12.1%)198/305 (64.9%)
Total D10503020/701 (0%)78/701 (11.1%)560/701 (79.9%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventRollover From D1050301Rollover From D1050325Rollover From D1050326Total D1050302
SchizophreniaPsychiatric disorders11/2710/1250/30511/701
Suicidal ideationPsychiatric disorders8/2711/1255/30514/701
AggressionPsychiatric disorders1/2713/1250/3054/701
Suicide attemptPsychiatric disorders1/2711/1256/3058/701
Bipolar I disorderPsychiatric disorders0/2710/1256/3056/701
Psychotic disorderPsychiatric disorders5/2710/1250/3055/701
Bipolar disorderPsychiatric disorders0/2710/1254/3054/701
DepressionPsychiatric disorders1/2710/1253/3054/701
Violence-related symptomPsychiatric disorders0/2711/1250/3051/701
Hand fractureInjury, poisoning and procedural complications0/2711/1252/3053/701
Most frequent other events
Showing 10 of 26
Most frequent other events
EventRollover From D1050301Rollover From D1050325Rollover From D1050326Total D1050302
HeadacheNervous system disorders65/27118/12573/305156/701
NasopharyngitisInfections and infestations24/27128/12526/30578/701
VomitingGastrointestinal disorders16/27127/12525/30568/701
NauseaGastrointestinal disorders34/2719/12550/30593/701
Weight increasedInvestigations21/27120/12529/30570/701
AnxietyPsychiatric disorders35/27114/12526/30575/701
SomnolenceNervous system disorders24/27114/12530/30568/701
Upper respiratory tract infectionInfections and infestations10/27114/12512/30536/701
AgitationPsychiatric disorders20/27114/12511/30545/701
CoughRespiratory, thoracic and mediastinal disorders11/27114/12514/30539/701

Baseline characteristics

There was one subject that never received study drug bringing the baseline population from 702 to 701

Age, Continuous
Age, Continuous(years)Rollover From D1050301Rollover From D1050325Rollover From D1050326Total
Mean15.5 ± 1.4411.1 ± 3.1214.4 ± 2.1814.3 ± 2.66
Age, Customized
Age, Customized(participants)Rollover From D1050301Rollover From D1050325Rollover From D1050326Total
Children (2-11 years)07536111
Adolescents (12-17 years)25750258565
Adults (18-64 years)1401125
Sex: Female, Male
Sex: Female, Male(Participants)Rollover From D1050301Rollover From D1050325Rollover From D1050326Total
Female10123152276
Male170102153425
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rollover From D1050301Rollover From D1050325Rollover From D1050326Total
Hispanic or Latino362154111
Not Hispanic or Latino235104251590
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rollover From D1050301Rollover From D1050325Rollover From D1050326Total
American Indian or Alaska Native0224
Asian1121023
Native Hawaiian or Other Pacific Islander0000
Black or African American38212685
White19796235528
More than one race2543261
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Rollover From D1050301Rollover From D1050325Rollover From D1050326Total
North America82125125332
South America2104061
Europe1570131288
Asia110920
08

Study locations

88 sites
  • Harmonex Neuroscience Research
    Dothan, Alabama 36303, United States
  • Diligent Clinical Trials, Inc
    Downey, California 90241, United States
  • University of California San Francisco Medical Center
    San Francisco, California 94143, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92701, United States
  • Sarkis Clinical Trials - Parent
    Gainesville, Florida 32607, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • APG Research, LLC
    Orlando, Florida 32803, United States
  • University of South Florida
    Saint Petersburg, Florida 33701, United States
  • Medical Research Group of Central Florida
    Sanford, Florida 32771, United States
  • University of South Florida Rothman Center of Neuropychiatry
    Tampa, Florida 33613, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Attalla Consultants, LLC
    Smyrna, Georgia 30080, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • University Of Kentucky
    Lexington, Kentucky 40509, United States
  • Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340
    Lake Charles, Louisiana 70601, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Neurobehavioral medicine Group, LLC
    Bloomfield Hills, Michigan 48302, United States
  • St. Charles Psychiatric Associates
    Saint Charles, Missouri 63301, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07753, United States
  • North Shore/Long Island Jewish PRIME
    Glen Oaks, New York 11004, United States
  • Dr. Jeanette Cueva
    Mount Kisco, New York 10549, United States
  • Montefiore Medical Center PRIME
    New York, New York 10467, United States
  • Finger Lakes Clinical Research
    Rochester, New York 10618, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University Nisonger Center
    Columbus, Ohio 43210, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • Family Psychiatry of The Woodlands, P.A.
    The Woodlands, Texas 77381, United States
  • Ericksen Research & Development, LLC
    Clinton, Utah 84015, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Neuroscience, Inc.
    Herndon, Virginia 20170, United States
  • Clinical Research Partners, LLC
    Petersburg, Virginia 23805, United States
  • Carilion Clinic
    Roanoke, Virginia 24014, United States
  • MHC - Ruse, EOOD
    Ruse, 7003, Bulgaria
  • UMHAT "Alexandrovska" EAD
    Sofia, 1431, Bulgaria
  • MHAT-Targovishte, AD
    Targovishte, 7700, Bulgaria
  • DCC "Mladost M" - Varna, OOD
    Varna, 9020, Bulgaria
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA
    Barranquilla, Colombia
  • E.S.E. Hospital Mental de Antioquia
    Bello, 0000, Colombia
  • Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda
    Bogota, 00000, Colombia
  • CHU Nantes - Hôpital Mère-Enfant
    Nantes Cedex 1, 44093, France
  • Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert
    Budapest, 1021, Hungary
  • Bekes Megyei Pandy Kalman Korhaz
    Gyula, 57--, Hungary
  • Seoul National University Hospital
    Seoul, Gyeonggi-do 110774, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, 501-757, Korea, Republic of
  • Inha University Hospital
    Incheon, 400-711, Korea, Republic of
  • Chonbuk National University Hospital
    Jeonju, 561-712, Korea, Republic of
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.
    Culiacan, Sinaloa 80020, Mexico
  • Dr. Jessica Rosas Escobar
    Durango, 34000, Mexico
  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
    Durango, 34000, Mexico
  • Accelerium S. de R.L. de C.V.
    Monterrey, 64000, Mexico
  • Instituto de Informacion de Investigacion en Salud Mental
    Monterrey, 64710, Mexico
  • Av Modesto Arreola #917 Ote. Col Centro
    Nuevo León, 64000, Mexico
  • Alexian Brothers Health and Wellness Center
    Davao City, 8000, Philippines
  • West Visayas State University Medical Center
    Iloilo, 5000, Philippines
  • National Center for Mental Health
    Mandaluyong City, 1553, Philippines
  • Veterans Memorial Medical Center
    Quezon City, 1101, Philippines
  • NZOZ Poradnia Zdrowia Psychicznego
    Kobierzyce, 55-040, Poland
  • Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Kliniczmy VI Psychiatrii Mlodziezy
    Toruń, 87-100, Poland
  • Centro de Investigacion Clinica Psiquiatrica
    Caguas, 00725, Puerto Rico
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
    Bucuresti, 041914, Romania
  • Spitalul Clinic de Psihiatrie Socola
    Iasi, 700282, Romania
  • Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu" Timisoara
    Timisoara, 300239, Romania
  • Sverdiovsk Regional Clinical Psychiatric Hospital
    Ekaterinburg, 62003, Russian Federation
  • GUZ Lipetsk Regional psychoneurological Hospital #1
    Lipetsk, 399313, Russian Federation
  • Closed corporation "Scientific Center of Personalized Psychiatry"
    Moscow, 119180, Russian Federation
  • Scientific Center of Personalized Psychiatry
    Moscow, 119180, Russian Federation
  • State Healthcare Institution of Nizhniy Novgordo region "Clinical Psychiatric Hospital #1 of City of Nizhniy Novgorod"
    Nizhny Novgorod, 603155, Russian Federation
  • SHI "City Psychoneurological dispensary #7 (with Hospital)"
    Saint Petersburg, 190005, Russian Federation
  • Center of Recovery Treatment "Pediatric Psychiatry" named after S.S. Mnukhin
    Saint Petersburg, 197022, Russian Federation
  • Bekhterev Institute
    Saint Petersburg, Russian Federation
  • Regional Clinical Mental Hospital of Saint Sofiya
    Saratow, 410060, Russian Federation
  • FSBSI "Scientific Research Institute of Mental Health"
    Tomsk, 634014, Russian Federation
  • State Healthcare Institution of Yaroslavl Rgion "Yaroslavl Regional clinical Mental Hospital"
    Yaroslavl, 150003, Russian Federation
  • Hospital Marítimo de Torremolinos
    Torremolinos, Málaga 29620, Spain
  • RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU
    Ivano Frankivsk, 76014, Ukraine
  • SI Institute of Neurology, Psychiatry and Narcology of NAMSU
    Kharkiv, 61068, Ukraine
  • SI Institute of Children and Adolescents Healthcare of NAMSU
    Kharkiv, 61153, Ukraine
  • TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions
    Kyiv, 04080, Ukraine
  • CI Lviv Regional Clinical Psychiatric Hospital
    Lviv, 79021, Ukraine
  • Odesa Regional Psychoneurological Dispensary, Outpatient Dept.
    Odesa, 65014, Ukraine
  • O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy
    Poltava, 36006, Ukraine
  • CI Kherson Regional Psychiatric Hospital of Kherson RC
    Stepanivka, 73488, Ukraine
  • Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU
    Ternopil, 46020, Ukraine
  • Reg. Psych. Hosp.n.a. O.Yuschenko, Dept. #121 VNMI
    Vinnitsia, 21018, Ukraine
09

References and documents

Publications

  • DelBello MP, Tocco M, Pikalov A, Deng L, Goldman R. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. J Child Adolesc Psychopharmacol. 2021 Sep;31(7):494-503. doi: 10.1089/cap.2021.0040. Epub 2021 Jul 29. PubMed 34324397 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Oct 2018, 60 months.

Results were first posted in Dec 2019, 1 year 2 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 60 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2013
First posted
Aug 2, 2013
StartActual
Sep 30, 2013
Primary completionActual
Oct 17, 2018
CompletionActual
Oct 17, 2018
Results first posted
Dec 19, 2019
Last update
Dec 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01914393
Responsible party
Sponsor
First posted
Aug 2, 2013
Start date
Sep 30, 2013
Primary completion
Oct 17, 2018
Completion
Oct 17, 2018
Results posted
Dec 19, 2019
Last update
Dec 19, 2019

Study contacts

Lurasidone Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion